Lees-Rolfe Garth 4
4 · Inhibikase Therapeutics, Inc. · Filed Jan 7, 2025
Insider Transaction Report
Form 4
Lees-Rolfe Garth
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-01-03+432,853→ 432,853 totalExercise: $1.58Exp: 2035-01-03→ Common Stock (432,853 underlying) - Award
Stock Option (Right to Buy)
2025-01-03+470,861→ 470,861 totalExercise: $1.26Exp: 2035-01-03→ Common Stock (470,861 underlying) - Award
Stock Option (Right to Buy)
2025-01-03+235,383→ 235,383 totalExercise: $1.45Exp: 2035-01-03→ Common Stock (235,383 underlying)
Footnotes (3)
- [F1]The options vested and became exercisable on October 9, 2024.
- [F2]The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.
- [F3]The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.